This conclusion is also supported by a corresponding increase in the ligands for CXCR3, CCR5 (e.g., CXCL9, CXCL10, CCL5) in both tumor and liver supernatants after treatment, whereas CXCR6 ligand (CXCL16) is higher only in the tumor (Extended Data Fig. 5g). This evidence concerns the gene CCL5 and neoplasm.